BioMarin’s BMN 290 Programme: An Update for the Friedreich’s Ataxia Community – Ataxia

BioMarin’s BMN 290 Programme: An Update for the Friedreich’s Ataxia Community

BioMarin’s BMN 290 Programme: An Update for the Friedreich’s Ataxia Community

We were disappointed to hear that on August 1, 2019 BioMarin announced plans to discontinue preclinical studies in the BMN 290 programme for Friedreich’s Ataxia. BMN 290 is a selective chromatin modulation therapy that has been under investigation as an active preclinical programme since 2017. Read the full press release from BioMarin here.

Posted 02/08/2019

SUBSCRIBE TO OUR NEWSLETTER

Something went wrong. Please check your entries and try again.
fundraise image

FUNDRAISE FOR US

Take part in a challenge or create your fundraiser. Every penny you raise will help those affected by ataxia.

Donate Image

DONATE

To make either a one off or recurring donation which will help fund research into treatments and cures and supports those affected ataxia

Volunteer Image

VOLUNTEER WITH US

Support the ataxia community and volunteer with Ataxia UK. From social media to telephone befriending, there are loads of ways you can make a difference to someone's life.

Donate Now
Welcome to our new site! We hope you like it.
As it's brand new, there may be a few temporary glitches such as broken links - we are working on getting these all fixed ASAP. If you'd like to give us any feedback or let us know if something isn't quite right, please email website@ataxia.org.uk
+
Scroll to Top